Evaluation of L-Alpha-Acetylmethadol (LAAM) in Methadone Patients - 5

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000356

Purpose

The purpose of this study is to determine the pharmacokinetics of L-alpha-acetylmethadol (LAAM) in adults transferred from methadone maintenance treatment for opiate dependence.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: LAAM	Phase II

Drug Information available for: Methadone Methadone hydrochloride Alphacetylmethadol Dimepheptanol Levomethadyl acetate Levomethadyl acetate hydrochloride Methadyl acetate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Pharmacokinetics of LAAM in Methadone Patients

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:	0
Study Start Date:	June 1991

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000356

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Charles O'Brien, M.D., Ph.D.

PDVAMC Treatment Research Center

More Information

Study ID Numbers:	NIDA-3-0012-5, Y01-3-0012-5
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000356
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Methadyl Acetate
Methadone
Mental Disorders

Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:

Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 15, 2009